Definition
Dulaglutide is a recombinant fusion protein that functions as a long-acting, selective glucagon-like peptide-1 (GLP-1) receptor agonist administered subcutaneous once weekly. It consists of two identical disulfide-linked chains, each containing a modified human GLP-1 analogue sequence covalently linked to a modified human immunoglobulin G4 (IgG4) heavy chain constant region (Fc) fragment. This structural modification increases its molecular size, preventing rapid renal filtration, and reduces its susceptibility to enzymatic degradation by dipeptidyl peptidase-4 (DPP-4). These features extend its half-life to approximately 5 days, enabling weekly dosing. Developed by Eli Lilly and Company, it is marketed under the brand name Trulicity for glycemic management in type 2 diabetes mellitus and the reduction of major adverse cardiovascular events. (FDA, Lilly)
Dulaglutide acts by binding to and activating the GLP-1 receptor, a membrane-bound protein located on pancreatic beta-cells and other target tissues. Upon activation, it stimulates intracellular cyclic AMP synthesis, prompting glucose-dependent insulin secretion. It also reduces glucagon secretion from alpha-cells when glucose levels are elevated, slows gastric emptying to limit postprandial glucose spikes, and acts on the central nervous system to decrease appetite and food intake. (NCBI, NEJM)
Identities
| Source Type | Identity |
|---|---|
| Wikipedia | Dulaglutide |
| Wikidata | Q15623081 |
| DBpedia | Dulaglutide |
| ProductOntology | N/A |
| Wiktionary | dulaglutide |
| Library of Congress Subject Headings (LCSH) | N/A |
| MeSH | dulaglutide |
| NCBI Taxonomy | N/A |
| AGROVOC | dulaglutide |
| Google Scholar | Dulaglutide cardiorenal outcomes Philippines |
| ConceptNet | dulaglutide |
| OpenCyc | N/A |
Also Known As
- Trulicity
- LY2189265
- Dulaglutide Injection
- Once-Weekly GLP-1 Agonist
Geography and Climate
In the tropical climate of the Philippines, where high humidity and ambient temperatures frequently exceed 30°C, the stability of dulaglutide is a key clinical consideration. Dulaglutide must be stored under refrigeration between 2°C and 8°C prior to use. Once a pen is taken out of the refrigerator, it can be kept at room temperature (up to 30°C) for up to 14 days. Exposure to temperatures above 30°C or direct sunlight can denature the fusion protein, rendering it inactive.
Healthcare providers in the Philippines advise patients to use insulated cooler bags containing gel ice packs when transporting dulaglutide from retail pharmacies. Patients living in provinces prone to seasonal typhoons and power outages must prepare alternative cooling storage options. The pre-filled, single-use pens are designed with a hidden needle to protect the sterile contents, but the plastic casing and electronic monitoring of pharmacy storage remains vulnerable to extreme ambient heat.
Demographics
The demographic profile of dulaglutide users in the Philippines is closely linked to the epidemiology of type 2 diabetes and its cardiovascular complications. The Philippine Society of Endocrinology, Diabetes and Metabolism (PSEDM) reports a high prevalence of diabetes among adults, especially in urban areas. Dulaglutide is primarily prescribed to adults with type 2 diabetes, particularly those with established cardiovascular disease or multiple cardiovascular risk factors, such as hypertension, dyslipidemia, or a history of smoking.
The target patient group in the Philippines includes working-class adults and elderly patients who value the convenience of a once-weekly injection over daily regimens. The simple design of the single-use pen, which does not require manual needle attachment or dose preparation, is popular among older patients with diabetic retinopathy or peripheral neuropathy, as well as busy professionals in major urban areas like Metro Manila, Cebu, and Davao.
Economy and Industry
Dulaglutide is distributed in the Philippines under the brand name Trulicity. It is available in major commercial pharmacy networks such as Mercury Drug and Watsons. As a high-cost biologic medication, it is primarily paid for out-of-pocket by patients. Public healthcare coverage through PhilHealth does not provide comprehensive reimbursement for modern GLP-1 receptor agonists, making long-term treatment a financial challenge for lower-income households.
The economic impact of dulaglutide includes its role in reducing hospitalizations for cardiovascular complications associated with diabetes. While the monthly cost of the medication is higher than oral therapies, clinical economic studies suggest that its cardiorenal benefits help offset long-term healthcare costs by lowering the rates of heart failure, myocardial infarction, and diabetic kidney disease, which are major financial burdens on families and the national health system.
Transportation and Infrastructure
The supply chain for dulaglutide in the Philippines depends on specialized cold-chain transportation networks. The medication is imported into central hubs in Manila, where it is stored in climate-controlled warehouses. Distribution to retail outlets across Luzon, Visayas, and Mindanao requires refrigerated container transport, refrigerated vans, and careful temperature logging to prevent freezing or overheating during transit.
In urban areas, the retail infrastructure supports reliable cold-chain storage, with pharmacies equipped with backup generators to maintain refrigeration during power interruptions. In remote provinces or island municipalities, the lack of continuous electricity and refrigerated logistics makes it difficult to maintain steady stocks of dulaglutide. Patients in these areas often rely on travel to larger cities to secure their prescriptions.
Culture and Tourism
The cultural perception of type 2 diabetes management in the Philippines has shifted toward therapies that offer cardiovascular protection and convenience. The weekly dosing schedule of dulaglutide fits well with the local lifestyle, reducing the daily burden of disease management. Unlike daily insulins, which can carry a social stigma when administered in public, the once-weekly home administration of dulaglutide offers patients greater privacy.
Medical tourism also impacts the utilization of dulaglutide in the country. Private medical centers and outpatient clinics in Manila provide specialized cardiometabolic care to expatriates and visiting patients. These clinics offer screening programs that evaluate cardiovascular and metabolic risks, prescribing weekly therapies like dulaglutide as part of comprehensive health management packages.
Government and Administration
The Philippine Food and Drug Administration (FDA) is responsible for regulating the registration, importation, and distribution of dulaglutide. The medication is classified as prescription-only (Rx), and pharmacies are required to verify a doctor’s prescription before dispensing it. The FDA monitors the retail market and online platforms to prevent the sale of unregistered or counterfeit dulaglutide pens, which present severe health risks due to unknown sterility and dosage.
The Department of Health (DOH) collaborates with professional medical societies to establish clinical standards for diabetes care. These guidelines emphasize the use of GLP-1 receptor agonists with proven cardiovascular benefits, such as dulaglutide, in high-risk diabetic patients. The Bureau of Customs ensures that incoming shipments of dulaglutide comply with national cold-chain transport regulations.
Education and Healthcare
Educational initiatives for healthcare professionals regarding dulaglutide are led by Eli Lilly, the PSEDM, and the Philippine College of Physicians (PCP). These educational programs focus on clinical evidence, such as the REWIND trial, which demonstrated dulaglutide’s effectiveness in reducing cardiovascular events in patients with and without established cardiovascular disease.
Patient training is a key part of prescribing dulaglutide. Healthcare providers, diabetes educators, and pharmacists teach patients how to use the single-dose pen. The education covers removing the bottom cap, placing the pen against the skin, unlocking the device, and pressing the injection button until the green indicator appears. Educators also advise patients on managing common gastrointestinal side effects, such as mild nausea, by adjusting meal sizes and staying hydrated.
Examples and Analogies
An analogy for dulaglutide is a weekly scheduled maintenance service for an industrial generator. Instead of a technician performing manual checks and adjustments every day (representing daily diabetes medications), the weekly maintenance program provides a long-lasting adjustment that keeps the system running smoothly for seven days. The program automatically regulates fuel flow (insulin secretion) and prevents sudden overloads (post-meal blood sugar spikes) while stabilizing the engine’s long-term performance and reducing wear on the machinery (cardiovascular protection).
A concrete example of dulaglutide’s design is its fusion to the IgG4 Fc fragment. This large antibody fragment acts as a shield, preventing the active GLP-1 molecule from being cleared by the kidneys or broken down by blood enzymes. This molecular structure allows the active peptide to circulate in the bloodstream for a week, providing a steady therapeutic effect without the need for daily injections.
Usage Scenarios
1. Glycemic and Cardiovascular Risk Management
A 63-year-old male in Pasig City with type 2 diabetes and a history of ischemic heart disease has an HbA1c of 8.2% on metformin and sulfonylurea therapy. Seeking to lower his blood sugar and reduce his risk of future cardiovascular events, his cardiologist and endocrinologist prescribe once-weekly injections of Trulicity at 0.75 mg, later titrated to 1.5 mg. Over six months, his HbA1c falls to 6.9%, and his blood pressure stabilizes.
2. Dosing Simplification for Elderly Patients
A 71-year-old grandmother in Iloilo City with type 2 diabetes struggles with daily insulin injections due to mild osteoarthritis in her hands. Her doctor transitions her to once-weekly dulaglutide. The simple click-and-inject design of the Trulicity pen, which requires no manual needle handling or dose configuration, allows her to administer her medication independently with improved compliance.
Strategies
- Titrate dulaglutide doses from 0.75 mg to 1.5 mg once weekly after a minimum of four weeks to allow the gastrointestinal tract to adapt and reduce nausea.
- Administer dulaglutide on the same day each week, at any time of day, with or without food, and rotate the injection site among the abdomen, thigh, and upper arm.
- If a dose is missed, administer it as soon as possible if there are at least 3 days (72 hours) until the next scheduled dose; otherwise, skip the missed dose.
- Eat slowly and avoid lying down immediately after meals to help manage temporary symptoms of delayed gastric emptying.
Security and Safety Measures
- Boxed Warning: Do not use dulaglutide in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Pancreatitis Warning: Discontinue dulaglutide immediately and do not restart if the patient experiences persistent, severe abdominal pain that may indicate acute pancreatitis.
- Kidney Function: Monitor kidney function in patients with renal impairment who report severe gastrointestinal side effects, as dehydration can lead to acute kidney injury.
- Diabetic Retinopathy: Monitor patients with a history of diabetic retinopathy for potential temporary worsening of the condition during rapid improvement of blood glucose levels.
Historical Context
Dulaglutide was developed by Eli Lilly to address the patient need for less frequent injections in diabetes management. Following extensive preclinical research, the drug entered clinical trials under the AWARD program, which compared its efficacy and safety to established therapies like metformin, exenatide, and insulin glargine. The US FDA approved Trulicity in September 2014. Subsequent findings from the REWIND trial expanded its clinical use by confirming its role in reducing primary cardiovascular events, leading to approvals for cardiovascular risk reduction.
In the Philippines, the introduction of Trulicity provided a weekly treatment option that changed the local clinical approach to type 2 diabetes. Endocrinologists welcomed the drug’s simple pen design and its cardioprotective properties, leading to its inclusion in national clinical consensus statements for managing type 2 diabetes patients with high cardiovascular risk.
Challenges and Controversies
Economic Barriers and Health Equity
The high cost of dulaglutide remains a barrier to access in the Philippines. Since the drug is paid for out-of-pocket, its benefits are largely limited to patients with higher incomes. This creates health equity challenges, as many lower-income patients who could benefit from its cardiovascular and renal protective properties cannot afford the monthly cost of therapy.
Dosing Confusion and Administration Errors
Although the dulaglutide pen is designed for ease of use, some patients experience confusion during their first administration. Errors include removing the cap too early, failing to unlock the pen, or lifting the device from the skin before the injection cycle is complete. Healthcare providers emphasize the need for thorough demonstrations to prevent accidental product waste.
Related Topic
- Liraglutide
- Semaglutide
- Cardiovascular Risk Factors
- Type 2 Diabetes
- Philippine Society of Endocrinology, Diabetes and Metabolism